In vitro activities of 21 antimicrobial agents alone and in combination with aminoglycosides or fluoroquinolones against extended-spectrum-β-lactamase-producing Escherichia coli isolates causing bacteremia.
Min Kyeong Cha, Cheol-In Kang, So Hyun Kim, Sun Young Cho, Young Eun Ha, Yu Mi Wi, Doo Ryeon Chung, Kyong Ran Peck, Jae-Hoon Song, Korean Network for Study on Infectious Diseases (KONSID)
Author Information
Min Kyeong Cha: Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, South Korea.
Cheol-In Kang: Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea collacin@hotmail.com.
So Hyun Kim: Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, South Korea Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Sun Young Cho: Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Young Eun Ha: Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Yu Mi Wi: Division of Infectious Diseases, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
Doo Ryeon Chung: Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, South Korea Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kyong Ran Peck: Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Jae-Hoon Song: Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, South Korea Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
We evaluated the in vitro activity of various antimicrobials alone and in combination against 291 extended-spectrum-β-lactamase-producing Escherichia coli (ESBL-EC) isolates causing bacteremia in South Korean hospitals. Ceftazidime, cefepime, and piperacillin-tazobactam in combination with amikacin showed greater activity than found in combination with ciprofloxacin. In settings with a high prevalence of ESBL-producing pathogens, combination aminoglycoside antimicrobial therapy, especially with amikacin, may be considered for empirical therapy against suspected Gram-negative sepsis as a carbapenem-saving strategy.
